After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

Key Takeaways Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's ...

An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

Oct 22 (Reuters) - Amgen (AMGN.O), opens new tab will launch ... biologic drugs that are comparable to generics of traditional pharmaceuticals. Unlike traditional drugs, complex biologic drugs ...

Oct 30 (Reuters) - Amgen (AMGN.O), opens new tab reported a higher quarterly profit on Wednesday, driven by a 24% rise in sales of drugs for high cholesterol and osteoporosis, and said mid-stage ...

While Regeneron may have lost its latest bid to block the launch of Amgen’s Eylea biosimilar Pavblu, the New York-based pharma isn’t throwing in the towel just yet. At the same time ...

With increasing chronic diseases, demand for personalized medicines, and adoption of AI, the biotech market is booming.

Amgen is one of the world's largest biotechnology ... GSK is one of the world's largest pharma companies. Leading products include Advair for asthma, Ventolin for bronchospasm and Theraflu for ...

Find out why Boehringer, Amgen and Novartis have been awarded the highest reputation scores by several cardiovascular patient ...